Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes (Q97586985)
Jump to navigation
Jump to search
scientific article published on 21 June 2020
Language | Label | Description | Also known as |
---|---|---|---|
English | Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes |
scientific article published on 21 June 2020 |
Statements
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes (English)
Rossana Berardi
Corrado Ficorella
Katia Cannita
Giampiero Porzio
Mariangela Torniai
Olga Nigro
Alessandro Tuzi
Raffaele Giusti
Biagio Ricciuti
Melissa Bersanelli
Domenico Galetta
Paolo Marchetti
Daniele Santini
Rita Chiari
Alex Friedlaender
Giuseppe L Banna
Federico Cappuzzo
Joachim G J V Aerts
Emilio Bria
Diego Cortinovis
Francesco Grossi
Maria R Migliorino
Francesco Passiglia
Francesca Mazzoni
Vincenzo Di Noia
Diego Signorelli
Alain Gelibter
Marianna Macerelli
Francesca Rastelli
Danilo Rocco
Alessandro Inno
Pietro Di Marino
Giovanni Mansueto
Federica Zoratto
Matteo Santoni
Marianna Tudini
Michele Ghidini
Marco Filetti
Annamaria Catino
Pamela Pizzutilo
Luca Sala
Mario Alberto Occhipinti
Fabrizio Citarella
Russano Marco
Luca Cantini
Alessandro Follador
Vincenzo Sforza
Miriam G Ferrara
Ettore D'Argento
Alessandro Leonetti
Linda Pettoruti
Lorenzo Antonuzzo
Simona Scodes
Lorenza Landi
Giorgia Guaitoli
Cinzia Baldessari
Federica Bertolini
Luigi Della Gravara
Maria Giovanna Dal Bello
Robert A Belderbos
Marco De Filippis
Cristina Cecchi
Serena Ricciardi
Clelia Donisi
Alessandro De Toma
Claudia Proto
Alfredo Addeo
Ornella Cantale
Carlo Genova
Alessandro Morabito